BioLargo Inc. (BLGO:OTCQX) has secured a key commercial channel through its Clyra Medical Technologies subsidiary, according to a September 3 release .
The exclusive agreement with Spartan Medical Inc. opens direct access to U.S. government healthcare facilities worldwide for the FDA-cleared ViaCLYR advanced wound irrigation solution.
This development creates a dedicated pathway for federal purchasing and distribution, strengthening Clyra's position as it scales manufacturing.
Why the Spartan Medical Agreement Matters Now
The deal represents Clyra's third reseller arrangement and specifically targets government buyers, including VA/DoD facilities. ViaCLYR has been added to the Defense Logistics Agency Electronic Catalog, making it available for resale across multiple federal agencies and certain VA-funded civilian hospitals. Spartan Medical, a veteran-owned contractor, will offer the product at parity pricing.
BioLargo CEO Dennis Calvert highlighted how this channel complements existing U.S. and international distribution partners while supporting revenue growth ahead of the planned national launch of the surgical product Bioclynse next year.
Company Advantage Through Clyrasept Technology
ViaCLYR is powered by Clyrasept Copper-Iodine Complex Solution. Clinical testing showed it kills 99.9999% of 18 pathogens within one minute and maintains 72-hour antimicrobial activity without reapplication. The solution is non-cytotoxic and does not require rinsing. The FDA 510(k) clearance covers cleansing, irrigating, and debriding wounds rather than an antimicrobial efficacy claim.
Clyra CEO Steve Harrison noted the technology addresses critical dimensions of wound care without tradeoffs, with particular relevance for veterans and service members treated in government facilities.
Key Assets and Next Catalysts
Clyra's portfolio includes the recently launched ViaCLYR and the upcoming Bioclynse surgical irrigation solution. First-half revenue reached US$154,000.
BioLargo's other platforms include ONM Environmental, serving municipal and industrial odor control customers, BLEST engineering services generating US$1.888 million in first-half revenue, and water treatment technology operating at a New Jersey site for over 10,000 hours.
BioLargo Energy Technologies continues development of its Cellinity battery with no revenue recorded yet.
Broader Sector Timing and Market Growth
The global wound care market is projected to grow from US$22.22 billion in 2025 to US$30.48 billion by 2030 at a 6.5% CAGR, driven by chronic conditions, surgical procedures, and aging populations.
The antimicrobial wound cleanser segment is expected to reach US$869.99 million by 2035. Hospitals represent about 52% of that segment, aligning with Clyra's government healthcare focus.
Analyst Views and Valuation Context
1Technical Analyst John Newell of John Newell & Associates issued a Speculative Buy rating in a March 11 report, citing Clyra's FDA clearance, patent portfolio, and measured commercialization approach across multiple cleantech markets.
Oak Ridge Financial Analyst Richard Ryan maintained a Buy rating, noting the hub-and-spoke subsidiary model helps manage risk while targeting high-growth areas.
Streetwise Ownership Overview*
BioLargo Inc. (BLGO:OTCQX)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 03/21/07 | NMED:OTCQX | 25 | BLGO:OTCQX | 1 |
| 11/20/02 | NWAY:OTCQX | 1 | NMED:OTCQX | 1 |
| 08/15/01 | LACI:OTCQX | 1 | NWAY:OTCQX | 1 |
Share Structure and Near-Term Events2
Insiders and management own about 13.73% of BioLargo, with institutions holding 0.04% on a 13F basis.
Market capitalization stands at US$31.23 million with 328.73 million shares outstanding. The stock trades in a 52-week range of US$0.08 to US$0.23.
Key Investor Takeaways
- Clyra secured an exclusive reseller agreement with Spartan Medical for government healthcare facilities and ECAT listing.
- ViaCLYR is FDA 510(k)-cleared for wound cleansing and irrigation with company-reported antimicrobial performance data.
- The agreement forms Clyra's third distribution channel alongside U.S. and 18-country international partners.
- BioLargo's broader portfolio spans medical, water treatment, odor control, and engineering, with first-half revenues reported across units.
- The wound care market is expanding at 6.5% CAGR through 2030, supporting demand for advanced cleansing solutions.
- Analysts maintain Buy and Speculative Buy ratings, citing commercialization strategy and multi-market exposure.
Common Questions from Investors
What does the Spartan Medical agreement provide? It grants Clyra an exclusive channel into U.S. government healthcare buyers through the ECAT catalog, covering VA/DoD, Federal Bureau of Prisons, Indian Health Service, and certain VA-funded civilian facilities.
What is ViaCLYR approved for? The FDA 510(k) clearance covers cleansing, irrigating, and debriding wounds such as burns, ulcers, and post-surgical sites, plus moistening dressings. Antimicrobial performance claims come from company testing.
How does this fit Clyra's rollout timeline? Spartan becomes the third reseller alongside existing U.S. and international partners. Manufacturing scale-up continues ahead of the Bioclynse surgical product launch next year.
What other BioLargo units are generating revenue? BLEST engineering posted US$1.888 million in first-half revenue, while ONM Environmental continues municipal and industrial sales under recurring contracts.
BioLargo continues executing across its cleantech platforms with the Spartan Medical channel providing a concrete step forward in the medical segment.
| Want to be the first to know about interesting Technology, Healthcare Services, Cleantech and Special Situations investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- BioLargo Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc. and Clyra Medical Technologies.
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
- Disclosure for the quote from the John Newell article published on March 11, 2026
- For the quoted article (published on March 11, 2026), BioLargo paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
- Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
John Newell Disclaimer
As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.
- Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
